Repligen Corporation (RGEN)

Market Cap	6.75B -14.1%
Revenue (ttm)	738.26M +16.4%
Net Income	48.89M
EPS	0.86
Shares Out	56.40M
PE Ratio	139.27
Forward PE	61.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	758,363
Open	120.81
Previous Close	115.29
Day's Range	118.56 - 122.89
52-Week Range	105.06 - 175.77
Beta	1.19
Analysts	Buy
Price Target	172.91 (+44.37%)
Earnings Date	Apr 28, 2026

About RGEN

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1981
• Employees: 2,000
• Stock Exchange: NASDAQ
• Ticker Symbol: RGEN
• Website: https://www.repligen.com

Analyst Summary

According to 11 analysts, the average rating for RGEN stock is "Buy." The 12-month stock price target is $172.91, which is an increase of 44.37% from the latest price.

Price Target

$172.91

(44.37% upside)

Analyst Consensus: Buy